Cumberland Pharmaceuticals Hits New 52-Week High of $6.51

Cumberland Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 6.51 on May 26, 2026. This achievement marks a remarkable increase in the stock's performance, reflecting a 306.34% rise over the past year, significantly outpacing the S&P 500's performance of 29.58% during the same period. As a microcap company in the Pharmaceuticals & Biotechnology industry, Cumberland Pharmaceuticals has a market capitalization of USD 46 million. Despite its recent stock performance, the company remains in a loss-making position, with a negative return on equity of -11.40% and a debt-to-equity ratio of -0.37. The stock's price-to-book ratio stands at 1.75, indicating its valuation relative to its book value. The stock's previous 52-week low was recorded at USD 1.85, highlighting the substantial growth it has experienced in the past year. This upward trend in Cumberland Pharmaceuticals' stock price underscores the company's evolving market position within the competitive pharmaceuticals landscape.